In breast cancer, a reduction in TERT methylation levels in cfDNA has been observed following effective treatment, suggesting that cfDNA analysis could serve as a potential biomarker for monitoring therapeutic efficacy in the future [248]. This evidence concerns the gene TERT and breast carcinoma.